Skip to content
TrialScanner

NCT04661007

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Phase 1/Phase 2Active, not recruitingINCYLead

Registry record

Lead sponsor
Incyte Biosciences Japan GK
Conditions
Non Hodgkins Lymphoma; Diffuse Large B-cell Lymphoma
Primary completion
Jul 1, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04661007 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04661007: To Assess the Safety and... | TrialScanner